Healthcare · Drug Manufacturers - Specialty & Generic
Made onAug 13, 2026
Price at call$73.54
6-month call Bull +12.6%
Target by Feb 2027$82.80
Great value below$60.00
Modelv0.6.0
Projection vs Actual
(6M history + forecast)
The masterbrain's trajectory (blue, curved through its 7 checkpoints), the deterministic v0.3 control (dashed), and the actual price (green) overlaid from the prediction date forward.
Forecast Change+12.6% to $82.80
Predicted High$82.80at 6 months
Predicted Low$73.90in 2 weeks
Forecast
The masterbrain trajectory — 7 dated checkpoints. Short rungs (2w, 1m) show the typical range as the primary claim; point calls run from 2 months out. Every claim still gets graded.
Predicted Aug 13, 2026 1:04 am
Bull
ZTS trends higher to
$82.80
(+12.6% from $73.54)
by Feb 2027.
flat-then-break
ThesisZTS is a high-quality animal-health compounder trading at a deep discount after a 42% drawdown, but sentiment is broken and there is no near-term catalyst. Expect base-building near current levels for weeks, then a gradual mean-reversion toward the composite fair value as the risk-on tape and quality bid re-emerge.
Invalidated ifA break below $65 on new guide-down news, or failure to reclaim $78 by month 3, would invalidate the recovery thesis.
Checkpointtime after the call
Datewhen it gets graded
Predictedthe claim: closing price
Current priceactual close — fills in over time
Predicted returnpredicted vs $73.54 at call
Conv.brain's confidence, 1–10
Driverwhy the brain put the point here
Prediction made
Aug 13, 2026
—
$73.54at call
—
—
The anchor — every point below is measured from this price and date.
2 weeks
Aug 27, 2026
$68.82–$78.26typical range · internal point $73.90
—
±6.4%
6/10
Base-building near lows, no catalyst, low beta
1 month
Sep 13, 2026
$66.69–$80.39typical range · internal point $74.80
—
±9.3%
5/10
Sentiment stabilizing, risk-on tape supportive
2 months
Oct 13, 2026
$76.50
—
+4.0%
5/10
Signal-adjusted fair value pulls price higher
3 months
Nov 13, 2026
$78.20
—
+6.3%
4/10
Q3 print approaches, quality bid returns
4 months
Dec 13, 2026
$80.00
—
+8.8%
4/10
Earnings beat likely, guide reset digested
5 months
Jan 13, 2027
$81.50
—
+10.8%
4/10
Value convergence toward DCF anchor
6 months
Feb 13, 2027
$82.80
—
+12.6%
3/10
Gradual re-rating toward composite fair value
Why ranges on the short rungs?
A 102-prediction trial (2026-07-21) showed 2-week point calls carry no information here —
three prompt formulations all lost to simply predicting zero — while the stock's own
volatility scale (σ×√t) described those windows well. So the short rungs claim what's
actually knowable: the typical travel, with earnings timing flagged where the variance
will come from. The internal point calls keep being generated and graded to map where
real skill begins. Full evidence: stocks/predictions/V0.5-DESIGN.md §8.
Deterministic control (v0.3 value line) targets
$80.72
(+9.8%)
— both lines get graded at every checkpoint, so the brain has to beat the formula, not just replace it.
Brain: claude-opus-4-7.